Literature DB >> 16391907

A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Stijn W T P J Heijmink1, Hilco van Moerkerk, Lambertus A L M Kiemeney, J Alfred Witjes, Ferdinand Frauscher, Jelle O Barentsz.   

Abstract

Transrectal ultrasound (TRUS) is an important tool for urologists and radiologists in the detection of prostate cancer. Various TRUS-guided biopsy techniques are applied in clinical practice. Frequently, only the detection rates achieved with these methods are compared. Other diagnostic performance parameters, particularly the specificity and negative predictive value, are seldom compared. After extensive assessment of the available literature, this review describes the methods of TRUS-guided biopsy for prostate cancer detection. A distinction was made between systematic biopsies and biopsies that target a perceived (hypoechoic or Doppler-enhancing) lesion on imaging. Subsequently, the diagnostic performance (sensitivity, specificity, positive and negative predictive values, accuracies) was compared between these techniques. Imaging-guided biopsy showed better diagnostic performance than systematic biopsy with higher sensitivity. The combinations of sensitivity and specificity were highest for colour Doppler and contrast-enhanced targeted biopsy. Studies targeting hypoechoic lesions had relatively high sensitivity, but specificity was low. Presently however, with widespread prostate-specific antigen screening, fewer prostate cancers are hypoechoic, and the value of targeting hypoechoic lesions has diminished. Performing colour or contrast-enhanced Doppler biopsy or adding these techniques to systematic biopsies improves diagnostic performance, particularly by increasing sensitivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391907     DOI: 10.1007/s00330-005-0035-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  91 in total

1.  The advances are significant improvements in both the microbubbles used as contrast agents and in the software that allows their selective detection.

Authors:  David Cosgrove
Journal:  Eur Radiol       Date:  2004-10       Impact factor: 5.315

2.  Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer.

Authors:  D Strohmeyer; C Rössing; F Strauss; A Bauerfeind; O Kaufmann; S Loening
Journal:  Prostate       Date:  2000-01       Impact factor: 4.104

3.  Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone.

Authors:  Andreas Erbersdobler; Henning Fritz; Silvia Schnöger; Markus Graefen; Peter Hammerer; Hartwig Huland; R Peter Henke
Journal:  Eur Urol       Date:  2002-01       Impact factor: 20.096

Review 4.  Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management.

Authors:  P J Littrup; S E Bailey
Journal:  Radiol Clin North Am       Date:  2000-01       Impact factor: 2.303

5.  Contemporary impact of transrectal ultrasound lesions for prostate cancer detection.

Authors:  Rahmi Onur; Peter J Littrup; J Edson Pontes; Fernando J Bianco
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

6.  Comparison of microscopic vascularity in benign and malignant prostate tissue.

Authors:  S A Bigler; R E Deering; M K Brawer
Journal:  Hum Pathol       Date:  1993-02       Impact factor: 3.466

7.  Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy.

Authors:  Herb Singh; Eduardo I Canto; Shahrokh F Shariat; Dov Kadmon; Brian J Miles; Thomas M Wheeler; Kevin M Slawin
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

8.  Cancer mortality surveillance--United States, 1990-2000.

Authors:  Sherri L Stewart; Jessica B King; Trevor D Thompson; Carol Friedman; Phyllis A Wingo
Journal:  MMWR Surveill Summ       Date:  2004-06-04

Review 9.  Epidemiology of prostate cancer.

Authors:  E David Crawford
Journal:  Urology       Date:  2003-12-22       Impact factor: 2.649

10.  Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy?

Authors:  Mesut Remzi; Michael Dobrovits; Andreas Reissigl; Vincent Ravery; Mattias Waldert; Christian Wiunig; Yan Kit Fong; Bob Djavan
Journal:  Eur Urol       Date:  2004-10       Impact factor: 20.096

View more
  25 in total

1.  [Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy].

Authors:  C Arsov; D Blondin; R Rabenalt; G Antoch; P Albers; M Quentin
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

Review 2.  Ultrasonography in prostate cancer: current roles and potential applications in radiorecurrent disease.

Authors:  James S Rosoff; Sandip M Prasad; Stephen J Savage
Journal:  World J Urol       Date:  2013-05-01       Impact factor: 4.226

3.  A new 5-grading score in the diagnosis of prostate cancer with real-time elastography.

Authors:  Guang Xu; Lijing Feng; Minghua Yao; Jian Wu; Lehang Guo; Xudong Yao; Lixia Zhao; Huixiong Xu; Rong Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Role of transrectal ultrasound in the diagnosis of extracapsular prostate cancer.

Authors:  Lucio Dell'atti
Journal:  J Ultrasound       Date:  2014-01-30

Review 5.  HistoScanningTM to Detect and Characterize Prostate Cancer-a Review of Existing Literature.

Authors:  James S Wysock; Alex Xu; Clement Orczyk; Samir S Taneja
Journal:  Curr Urol Rep       Date:  2017-10-24       Impact factor: 3.092

6.  Factors influencing the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography: correlation with biopsy and radical prostatectomy specimens.

Authors:  J Jiang; Y-Q Chen; Y-K Zhu; X-H Yao; J Qi
Journal:  Br J Radiol       Date:  2012-06-14       Impact factor: 3.039

7.  Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  World J Urol       Date:  2018-03-05       Impact factor: 4.226

8.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy.

Authors:  Alexandre Ben Cheikh; Nicolas Girouin; Marc Colombel; Jean-Marie Maréchal; Albert Gelet; Alvine Bissery; Muriel Rabilloud; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

9.  Prostate cancer: a comparison of the diagnostic performance of transrectal ultrasound versus contrast enhanced transrectal ultrasound in different clinical characteristics.

Authors:  Hongli Li; Jianguo Xia; Shaowei Xie; Yifen Guo; Mei Xin; Fenghua Li
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  Doppler spectral waveform parameters at neurovascular bundle vessels in patients with prostate biopsy.

Authors:  Yuh-Shyan Tsai; Yeong-Chin Jou; Chia-Hong Chen; Chien-Chen Chang; Wen-Horng Yang; Jan-Li Lai; Tzong-Shin Tzai
Journal:  J Endourol       Date:  2013-12-28       Impact factor: 2.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.